Alibaba Health Information Technology : GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the shares in Alibaba Health Information Technology Limited.

ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿 里 健 康 信 息 技 術 有 限 公 司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS

GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS

On September 15, 2020, the Company granted 119,000 Options to one Grantee and 4,259,476 RSUs to 127 Grantees in accordance with the terms of the Share Award Scheme, subject to acceptance.

SHARE OPTIONS

On September 15, 2020, the Company granted 119,000 Options to one Grantee in accordance with the terms of the Share Award Scheme, subject to acceptance.

Details of the Grant

The details of the Options granted to the Grantee are as follows:

- 1 -

The Options granted are not subject to performance targets.

Exercise Price

The exercise price of the Options of HK$18.66 per Share represents the highest of (i) the closing price of the Shares of HK$18.66 per Share as stated in the daily quotation sheet issued by the Stock Exchange on the Date of Grant, (ii) the average closing price of the Shares of HK$17.94 per Share as stated in the daily quotation sheets issued by the Stock Exchange for the five business days immediately preceding the Date of Grant, and (iii) the nominal value of each Share, which is HK$0.01.

Connected Grantee

119,000 Options are granted to one Connected Grantee who is a director of certain subsidiaries of the Company.

RESTRICTED SHARE UNITS

On September 15, 2020, the Company granted 4,259,476 RSUs to 127 Grantees in accordance with the terms of the Share Award Scheme, subject to acceptance. In accordance with the terms of the Share Award Scheme, the RSUs were granted to the Grantees under the following terms:

• each of the RSUs to be granted to the Grantees represents a right to receive a Share on the date the RSU vests; and
• the RSUs granted are not subject to performance targets.

- 2 -

In relation to 4,211,876 RSUs granted to the Non-connected Grantees who are not connected persons of the Company, new Shares that rank pari passu in all respects among themselves and with all the Shares in issue from time to time shall be issued to such Non-connected Grantees upon vesting and settlement of such RSUs. In relation to 47,600 RSUs granted to the Connected Grantee, the Company shall procure the Trustee to purchase existing Shares from the market out of cash contribution by the Company to be held on trust for the Connected Grantee until such RSUs are vested with such Connected Grantee.

The RSUs granted typically shall vest in the Grantees within four years from the Date of Grant.

Connected Grantee

47,600 RSUs are granted to one Connected Grantee, who is a director of certain subsidiaries of the Company.

LISTING RULES IMPLICATIONS

The grant of RSUs to the Connected Grantee constituted a connected transaction of the Company under Chapter 14A of the Listing Rules. However, no new Shares will be issued and allotted upon vesting and settlement of such RSUs granted to the Connected Grantee. As the RSUs were granted to the Connected Grantee pursuant to her service contract with a subsidiary of the Company, the grant of RSUs to the Connected Grantees is exempt from reporting, announcement and independent shareholders' approval requirements under Rule 14A.73 of the Listing Rules.

REASONS FOR AND BENEFITS OF THE GRANTS

The purposes of the aforesaid grant of the Options and RSUs are (i) to attract skilled and experienced personnel for the further development and expansion of the Group by providing them with the opportunity to acquire equity interests in the Company, (ii) to recognize the contribution to the success and development of the Group made by the existing employees of Company or its affiliate(s), and/or (iii) generally to incentivize and motivate our employees to remain with, and to strive for the future development and expansion of, the Group.

- 3 -

- 4 -

Hong Kong, September 15, 2020

As at the date of this announcement, the Board comprises eight Directors, of which (i) two are executive Directors, namely Mr. ZHU Shunyan and Mr. WANG Qiang; (ii) three are non-executive Directors, namely Mr. WU Yongming, Mr. WANG Lei and Mr. XU Hong; and (iii) three are independent non-executive Directors, namely Mr. LUO Tong, Mr. WONG King On, Samuel and Ms. HUANG Yi Fei (Vanessa).

- 5 -